<DOC>
	<DOCNO>NCT01757236</DOCNO>
	<brief_summary>The purpose study evaluate efficacy oral linezolid-rifampin combination therapy ( 4 6 week ) versus standard care treatment Gram-positive prosthetic hip joint infection one-stage surgical treatment .</brief_summary>
	<brief_title>Efficacy Safety Study Antibiotic Treatment Treat Hip Prosthetic Joint Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Arthritis , Infectious</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>1 . Men woman ≥ 18 ≤ 80 year age , weight ≥ 40 kg , BMI &lt; 35 , receive diagnosis chronic PJI ( last 4 week less 24 month ) require onestage surgical procedure present least ONE follow clinical sign symptom : 1 . Joint pain 2 . Effusion 3 . Erythema sensation heat implant site 4 . Limited range motion affect joint 2 . Intraoperative microbiological specimen : surgical resection , 5 separate surgical specimen ( least 3 ) must send culture susceptibility test . These specimen must take different location : Hip capsule , femoral membrane , acetabular membrane , synovium , synovial fluid separate instrument . A minimum 2 surgical specimen must positive . If preoperative puncture reveal presence acceptable ( Gram+ ) pathogen , acceptable one pathogen similar previously reveal one identify surgical procedure . 3 . Documented presence Grampositive bacteria sole pathogen responsible infection . Note : This criterion must verify obtain result susceptibility test perform specimen take surgical procedure . The verification occur Day 2 Day 7 study . 4 . All patient must undergo 1stage revision surgery . 5 . IRB IEC approve informed consent form sign date . Informed consent obtain patient participation research study . If patient unable give consent , may obtain patient 's next kin legal representative accordance current law regulation . 6 . Willing able comply schedule visit , 6 week treatment study antibiotic , laboratory test , study procedure . 7 . Patient entitle Health System benefit benefit 1 . Concerning woman childbearing age : 1. intake oral contraceptive ( estroprogestins progestin ) 2. unability use adequate mechanical contraceptive precaution 3. positive pregnancy test result within 72 hour prior randomization 4. pregnant , currently breastfeed unwilling discontinue breastfeed therapy 2 . Patients prosthetic joint infection cause : Gramnegative , mixed Gramnegative Grampositive , fungal , mycobacterial microorganism . If previous radiologically guided puncture reveal presence Gramnegative microorganism , patient must enrol study . 3 . Platelet count le 100 ×103/mm3 time examination perform screening period . 4 . Hemoglobin &lt; 9 g/dL time examination perform screening period . 5 . Infection affect several joint . 6 . Rheumatological disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , etc . ) 7 . Previously diagnose immune function disease ( ) ( e.g. , AIDS ) , neutropenia ( neutrophil &lt; 1000/mm3 ) . 8 . Alcoholism substance abuse sufficient , investigator 's judgment , prevent treatment adherence study drug and/or followup . 9 . Patients currently peritoneal dialysis receive another treatment renal failure ( e.g. , hemofiltration , CVVH ) . 10 . Liver failure alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) and/or total bilirubin level upper egal 5 time upper limit normal . 11 . Patients concurrent serious infection : endocarditis , meningitis , central nervous system ( CNS ) infection , decubitus ischemic ulcer underlie osteomyelitis , necrotizing fasciitis , gas gangrene . If suspect , diagnose must rule prior enrollment study . 12 . Previous randomization protocol . 13 . Not expect likely survive entire duration treatment period TOC ( 12 month end treatment ) . 14 . Hypersensitivity study drug excipients . 15 . Identification pathogen resistant investigational drug . 16 . Patients treat protease inhibitor ( e.g . indinavir , ritonavir ) , delavirdine , nevirapine . 17 . Patients treat treat within two week prior surgery MAOI ( A B ) , antiserotonergic drug , tricyclic antidepressant , agonist 5HT1receptor ( triptan ) , direct indirect sympathomimetic drug ( include adrenergic bronchodilator , pseudoephedrin , phenylpropanolamin ) , vasopressor ( adrenalin , noradrenalin ) , dopaminergic drug , pethidin buspirone , 18 . Patients degenerative neurological disease ( Parkinson 's disease , multiple sclerosis , Alzheimer 's disease , etc. ) . 19 . Patient present uncontrolled hypertension , pheochromocytoma , carcinoid syndrome , hyperthyroidism , bipolar depression , dysthymic schizophrenia , acute confusional state , pophyria history retrobulbar optic neuritis . 20 . Patient participate participated clinical trial month prior study screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Antibiotic</keyword>
	<keyword>linezolid</keyword>
	<keyword>linezolid/rifampin</keyword>
</DOC>